source
- Novo Nordisk sues Eli Lilly over alleged misleading obesity drug adsNovo Nordisk filed a lawsuit in a New Jersey federal court accusing Eli Lilly of deceptive advertising for its GLP-1 obesity medicines. The action follows a cease-and-desist request that asked Lil…
- Novartis says it will keep seeking sub-$2 billion bolt-on deals worldwide, staying geography-agnosticNovartis CEO Vas Narasimhan told investors on the second‑quarter earnings call that the company will continue to pursue bolt‑on acquisitions below $2 billion and has no plans to overhaul its busine…